Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flotetuzumab in Relapsed/Refractory AML or MDS
NCT02152956Phase 2Terminated
- Sponsor
- MacroGenics
- Start
- Jun 2014
- Primary completion
- Jul 2022
- Modality
- Bispecific Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of flotetuzumab in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by MacroGenics. Started Jun 2014; status: terminated.
02
Drugs
flotetuzumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02152956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02152956.